688192 迪哲医药
已收盘 12-17 15:00:01
资讯
新帖
简况
迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%
证券之星 · 12-17 22:37
迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%
迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%
证券之星 · 12-15 22:34
迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%
迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐
中金财经 · 12-11
迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐
迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据
中金财经 · 12-10
迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据
迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布
智通财经 · 12-09
迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布
迪哲医药选举康晓静为职工董事
中金财经 · 11-25
迪哲医药选举康晓静为职工董事
迪哲医药（688192）公司公告选举职工董事，11月24日股价上涨2.27%
证券之星 · 11-24
迪哲医药（688192）公司公告选举职工董事，11月24日股价上涨2.27%
每周股票复盘：迪哲医药（688192）张小林获177.5万股归属上市
证券之星 · 11-16
每周股票复盘：迪哲医药（688192）张小林获177.5万股归属上市
迪哲医药涨6.36%，中国银河一周前给出“买入”评级
证券之星 · 11-13
迪哲医药涨6.36%，中国银河一周前给出“买入”评级
迪哲医药（688192）披露限制性股票激励计划部分归属结果暨股票上市公告，11月10日股价上涨0.85%
证券之星 · 11-10
迪哲医药（688192）披露限制性股票激励计划部分归属结果暨股票上市公告，11月10日股价上涨0.85%
每周股票复盘：迪哲医药（688192）舒沃哲高瑞哲进医保加速放量
证券之星 · 11-09
每周股票复盘：迪哲医药（688192）舒沃哲高瑞哲进医保加速放量
迪哲医药(688192.SH)：高瑞哲®和Birelentinib多项研究入选第67届美国临床血液学会(ASH)大会
智通财经 · 11-04
迪哲医药(688192.SH)：高瑞哲®和Birelentinib多项研究入选第67届美国临床血液学会(ASH)大会
迪哲医药：11月3日召开业绩说明会
证券之星 · 11-04
迪哲医药：11月3日召开业绩说明会
图解迪哲医药三季报：第三季度单季净利润同比增长5.20%
证券之星 · 10-30
图解迪哲医药三季报：第三季度单季净利润同比增长5.20%
迪哲医药(688192)9月30日股东户数0.88万户，较上期增加5.01%
证券之星 · 10-30
迪哲医药(688192)9月30日股东户数0.88万户，较上期增加5.01%
每周股票复盘：迪哲医药（688192）两日现大宗交易机构合计净卖出879.63万元
证券之星 · 10-26
每周股票复盘：迪哲医药（688192）两日现大宗交易机构合计净卖出879.63万元
10月21日迪哲医药现1笔大宗交易 机构净卖出444.31万元
证券之星 · 10-21
10月21日迪哲医药现1笔大宗交易 机构净卖出444.31万元
迪哲医药（688192）4176.48万股限售股将于10月20日解禁，占总股本9.09%
证券之星 · 10-20
迪哲医药（688192）4176.48万股限售股将于10月20日解禁，占总股本9.09%
每周股票复盘：迪哲医药（688192）4176万股限售股将解禁
证券之星 · 10-12
每周股票复盘：迪哲医药（688192）4176万股限售股将解禁
迪哲医药（688192）披露向特定对象发行限售股上市流通公告，10月10日股价下跌3.89%
证券之星 · 10-10
迪哲医药（688192）披露向特定对象发行限售股上市流通公告，10月10日股价下跌3.89%
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲、Birelentinib、DZD6008。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":57.5,"timestamp":1765954801000,"preClose":57.01,"halted":0,"volume":1602417,"delay":0,"changeRate":0.0086,"floatShares":453000000,"shares":461000000,"eps":-1.8809,"marketStatus":"已收盘","change":0.49,"latestTime":"12-17 15:00:01","open":57,"high":57.87,"low":56.43,"amount":91853400,"amplitude":0.0253,"askPrice":57.53,"askSize":2,"bidPrice":57.5,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-1.8809,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":57.01,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":62.71,"lowLimit":51.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":461187894,"isCdr":false,"pbRate":18.41,"roa":"--","roe":"--","epsLYR":-2.04,"committee":-0.303704,"marketValue":26518000000,"turnoverRate":0.0035,"status":0,"afterMarket":{"amount":0,"volume":0,"close":57.5,"buyVolume":0,"sellVolume":0,"time":1765956837768,"indexStatus":"已收盘 12-17 15:30:00","preClose":57.01},"floatMarketCap":26063000000},"requestUrl":"/m/hq/s/688192/wiki","defaultTab":"wiki","newsList":[{"id":"2592916301","title":"迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916301","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592916301?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:37","pubTimestamp":1765982244,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，迪哲医药报收于57.5元，较前一交易日上涨0.86%，最新总市值为265.18亿元。近日，迪哲医药发布关于2022年限制性股票激励计划首次授予及预留授予部分限制性股票符合归属条件的公告。公告显示，公司于2025年12月16日召开董事会，审议通过相关议案，确认2022年限制性股票激励计划中首次授予的第一类激励对象第三个归属期、第二类激励对象第二个归属期以及预留授予激励对象第一个归属期的归属条件均已达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2591642135","title":"迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642135","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642135?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:34","pubTimestamp":1765809251,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，迪哲医药报收于58.54元，较前一交易日下跌5.73%，最新总市值为269.98亿元。该股当日开盘61.52元，最高61.62元，最低58.54元，成交额达1.98亿元，换手率为0.73%。公司近日发布公告，披露关于2020年员工股份期权计划第二个行权期第一次行权限售股上市流通的相关情况。该部分股份于2022年12月23日完成登记，限售期为36个月，上市流通日期为2025年12月23日。保荐机构华泰联合证券对本次限售股上市流通无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2590466593","title":"迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2590466593","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590466593?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:07","pubTimestamp":1765440426,"startTime":"0","endTime":"0","summary":"中国经济网北京12月11日讯 迪哲医药 近日发布2025年第三季度报告显示，2025年第三季度，公司实现营业收入2.31亿元，同比增长71.46%；归属于上市公司股东的净利润-2.03亿元；归属于上市公司股东的扣除非经常性损益的净利润-2.11亿元。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。 迪哲医药2次募资合计募集资金38.99亿元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/11/20251211208540.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/11/20251211208540.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251211/31859232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0196","LU1794554557.SGD","LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","BK1521","LU1328615791.USD","159982","BK1516","BK1147","LU1720050803.USD","LU2289578879.USD","BK0276","LU1997244956.HKD","BK0239","LU1655091616.SGD","BK0183","LU1064130708.USD","688192","LU2495084118.USD","LU1997245177.USD","LU1064131003.USD","06030","BK0012","LU1255011170.USD","LU1997245094.SGD","600030","BK0028","399300","BK1564"],"gpt_icon":0},{"id":"2590583770","title":"迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583770","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583770?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:56","pubTimestamp":1765360604,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司在第67届美国临床血液学会年会上，公布了其两款全球首创新药在淋巴瘤治疗领域的最新临床研究进展。另一方面，其非共价LYN/BTK双靶点抑制剂Birelentinib在B细胞淋巴瘤领域取得新进展。公司同时披露了Birelentinib联合疗法治疗弥漫性大B细胞淋巴瘤的后续研究计划。这些数据进一步验证了迪哲医药两款核心产品的临床价值，为其在淋巴瘤治疗领域的商业化前景提供了支持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31856740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688192","LU2463526074.USD","BK0239","ASH","BK4109"],"gpt_icon":0},{"id":"2590131413","title":"迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590131413","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590131413?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:43","pubTimestamp":1765266190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 公告，公司第67届美国临床血液学会大会上，公布了公司自主研发的两款全球首创新药的最新研究成果：高选择性JAK1抑制剂高瑞哲在T细胞淋巴瘤领域取得多项新进展，以及非共价LYN/BTK双靶点抑制剂birelentinib在B细胞淋巴瘤治疗领域的最新临床数据。本次ASH大会，迪哲公布了该研究的最新随访数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2586469554","title":"迪哲医药选举康晓静为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2586469554","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586469554?lang=zh_cn&edition=full","pubTime":"2025-11-25 13:04","pubTimestamp":1764047048,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司于2025年11月21日召开职工代表大会，选举康晓静女士为公司职工董事。此次会议以电子通信方式举行，共有105名职工代表出席，符合法定人数。根据会议决议，康晓静女士的任期自决议通过之日起至公司第二届董事会任期届满之日止。公告显示，康晓静女士现任公司财务主管，持有公司股票17,000股，其任职资格符合《公司法》及《公司章程》的相关规定。此次选举完成后，公司董事会中兼任高级管理人员及由职工代表担任的董事总数未超过董事总数的二分之一，符合监管要求。这一人事变动是公司完善治理结构的一部分，旨在保障职工参与企业民主管理的权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251125/31821755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2585498454","title":"迪哲医药（688192）公司公告选举职工董事，11月24日股价上涨2.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498454","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498454?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:33","pubTimestamp":1763994809,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，迪哲医药报收于63.59元，较前一交易日上涨2.27%，最新总市值为293.27亿元。近日，迪哲（江苏）医药股份有限公司发布公告称，公司于2025年11月21日召开职工代表大会，选举康晓静女士为公司职工董事，任期自决议通过之日起至第二届董事会任期届满。康晓静女士现任公司财务主管，具备相关法律法规规定的董事任职资格。本次选举后，职工代表董事及兼任高管的董事人数未超过董事总数的二分之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2583596396","title":"每周股票复盘：迪哲医药（688192）张小林获177.5万股归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596396","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583596396?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:13","pubTimestamp":1763230393,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，迪哲医药报收于65.25元，较上周的59.77元上涨9.17%。本周关注点公司公告汇总：董事长张小林获1,775,000股限制性股票归属，新增股份将于2025年11月13日上市。股本股东变化：公司总股本由459,412,894股增至461,187,894股，因限制性股票归属导致股本变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2583404554","title":"迪哲医药涨6.36%，中国银河一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2583404554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583404554?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:28","pubTimestamp":1763022490,"startTime":"0","endTime":"0","summary":"今日迪哲医药涨6.36%，收盘报65.58元。2025年11月3日，中国银河研究员程培,闫晓松发布了对迪哲医药的研报《迪哲医药2025年三季报业绩点评：舒沃替尼海外获批，创新管线持续推进》，该研报对迪哲医药给出“买入”评级。研报中预计公司2025-2027年的营业收入分别为7.88/16.47/30.38亿元；归母净利润分别为-6.32/-1.16/5.10亿元，公司合理市值区间为350.30-502.32亿元，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为75.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","601881"],"gpt_icon":0},{"id":"2582087751","title":"迪哲医药（688192）披露限制性股票激励计划部分归属结果暨股票上市公告，11月10日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582087751","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582087751?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:27","pubTimestamp":1762784871,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，迪哲医药报收于60.28元，较前一交易日上涨0.85%，最新总市值为276.93亿元。近日，迪哲医药发布《2022年限制性股票激励计划首次授予部分第一类激励对象第二个归属期归属结果暨股票上市公告》。公告显示，公司已完成2022年限制性股票激励计划首次授予部分第一类激励对象第二个归属期的股份登记，本次归属新增股份1,775,000股，上市流通日期为2025年11月13日，股票来源为公司向激励对象定向发行A股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2582986986","title":"每周股票复盘：迪哲医药（688192）舒沃哲高瑞哲进医保加速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2582986986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582986986?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:20","pubTimestamp":1762626024,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，迪哲医药报收于59.77元，较上周的63.7元下跌6.17%。本周，迪哲医药11月3日盘中最高价报66.0元。舒沃哲和高瑞哲已顺利进入医保目录，进入医保后保持较高的增长速度，2025年前三季度，公司实现营业收入5.86亿元，同比增长73%。公司坚持源头创新，已建立七款具备全球竞争力的临床产品管线，其中舒沃哲已在中、美两国获批上市，高瑞哲已在中国获批上市，两款中国上市的产品均已纳入国家医保目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2580785963","title":"迪哲医药(688192.SH)：高瑞哲®和Birelentinib多项研究入选第67届美国临床血液学会(ASH)大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580785963","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580785963?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:12","pubTimestamp":1762247572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司将于12月6日至9日在第67届美国临床血液学会(American Society of Hematology，ASH)大会上，公布淋巴瘤治疗领域两大核心产品高瑞哲®(通用名：戈利昔替尼胶囊)和birelentinib(DZD8586)多项最新研究成果。本次大会，公司共有15篇摘要入选，充分展现了公司在血液肿瘤治疗领域的丰富管线组合以及研发潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239","LU2463526074.USD","BK4109","ASH"],"gpt_icon":0},{"id":"2580580271","title":"迪哲医药：11月3日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580580271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580580271?lang=zh_cn&edition=full","pubTime":"2025-11-04 10:32","pubTimestamp":1762223555,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月3日迪哲医药发布公告称公司于2025年11月3日召开业绩说明会。舒沃哲和高瑞哲已顺利进入医保目录，进入医保后保持较高的增长速度，2025年前三季度，公司实现营业收入5.86亿元，同比增长73%。迪哲医药主营业务：创新药的研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400011064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2579459441","title":"图解迪哲医药三季报：第三季度单季净利润同比增长5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579459441","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579459441?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:53","pubTimestamp":1761825219,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药2025年三季报显示，前三季度公司主营收入5.86亿元，同比上升73.23%；归母净利润-5.8亿元，同比下降3.85%；扣非净利润-6.31亿元，同比下降5.19%；其中2025年第三季度，公司单季度主营收入2.31亿元，同比上升71.46%；单季度归母净利润-2.03亿元，同比上升5.2%；单季度扣非净利润-2.11亿元，同比上升3.35%；负债率51.15%，财务费用2269.98万元，毛利率95.68%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"gpt_icon":0},{"id":"2579118540","title":"迪哲医药(688192)9月30日股东户数0.88万户，较上期增加5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118540?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816497,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2025年9月30日公司股东户数为8806.0户，较6月30日增加420.0户，增幅为5.01%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，迪哲医药区间涨幅为21.12%，在此期间股东户数增加420.0户，增幅为5.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2578077875","title":"每周股票复盘：迪哲医药（688192）两日现大宗交易机构合计净卖出879.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578077875","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578077875?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:05","pubTimestamp":1761422716,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，迪哲医药报收于60.47元，较上周的65.45元下跌7.61%。本周，迪哲医药10月20日盘中最高价报66.0元。10月23日盘中最低价报58.19元。迪哲医药当前最新总市值277.81亿元，在化学制药板块市值排名15/150，在两市A股市值排名676/5160。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2577828289","title":"10月21日迪哲医药现1笔大宗交易 机构净卖出444.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577828289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577828289?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:23","pubTimestamp":1761038597,"startTime":"0","endTime":"0","summary":"证券之星消息，10月21日迪哲医药发生大宗交易，交易数据如下：大宗交易成交价格64.08元，成交6.93万股，成交金额444.31万元，买方营业部为中信证券股份有限公司总部，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交1386.0手。截至2025年10月21日收盘，迪哲医药报收于64.08元，上涨2.07%，换手率1.13%，成交量5.12万手，成交额3.24亿元。该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为94.88。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100026734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2576800217","title":"迪哲医药（688192）4176.48万股限售股将于10月20日解禁，占总股本9.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576800217","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576800217?lang=zh_cn&edition=full","pubTime":"2025-10-20 08:02","pubTimestamp":1760918559,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于10月20日将有4176.48万股限售股份解禁，为公司定向增发机构配售股份，占公司总股本9.09%。最近一年内，该股累计解禁2.87亿股，占总股本的62.39%。本次解禁后，公司还有792.0万股限售股份，占总股本1.72%。迪哲医药主营业务：创新药的研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000001829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2574463629","title":"每周股票复盘：迪哲医药（688192）4176万股限售股将解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2574463629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574463629?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:54","pubTimestamp":1760212452,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，迪哲医药报收于67.78元，较上周的72.43元下跌6.42%。本周，迪哲医药10月9日盘中最高价报73.0元。公司公告汇总迪哲（江苏）医药股份有限公司向特定对象发行的41,764,808股限售股将于2025年10月20日起上市流通，占公司总股本的9.09%。该次发行新增股份于2025年4月18日完成登记，限售期为自发行结束之日起六个月。保荐机构华泰联合证券对本次限售股上市流通无异议。本次上市后，相关股东剩余限售股数量为零。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200001039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2574170168","title":"迪哲医药（688192）披露向特定对象发行限售股上市流通公告，10月10日股价下跌3.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574170168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574170168?lang=zh_cn&edition=full","pubTime":"2025-10-10 22:59","pubTimestamp":1760108352,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，迪哲医药报收于67.78元，较前一交易日下跌3.89%，最新总市值为311.39亿元。近日，迪哲医药发布向特定对象发行限售股上市流通公告。公告称，公司向特定对象发行的41,764,808股限售股将于2025年10月20日起上市流通，占公司总股本的9.09%。该次发行新增股份于2025年4月18日完成登记，限售期为自发行结束之日起六个月。保荐机构华泰联合证券对本次限售股上市流通无异议。本次上市后，相关股东剩余限售股数量为零。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000039914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765999419813,"stockEarnings":[{"period":"1week","weight":-0.0763},{"period":"1month","weight":-0.0982},{"period":"3month","weight":-0.1904},{"period":"6month","weight":-0.0551},{"period":"1year","weight":0.2895},{"period":"ytd","weight":0.3865}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8806人(较上一季度增加5.01%)","perCapita":"51810股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46118万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲、Birelentinib、DZD6008。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}